Immunocore Holdings plc Current Income Tax Expense (Benefit)
Immunocore Holdings plc (IMCR) reported Current Income Tax Expense (Benefit) of $1.62 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-02-25
- Immunocore Holdings plc current income tax expense (benefit) for fiscal 2025 was $1.62M, a 17.69% decline from fiscal 2024.
- Immunocore Holdings plc current income tax expense (benefit) for fiscal 2024 was $1.97M, a 722.08% increase from fiscal 2023.
- Immunocore Holdings plc current income tax expense (benefit) for fiscal 2023 was $240.00K, a 98.21% decline from fiscal 2022.
- Immunocore Holdings plc current income tax expense (benefit) for fiscal 2022 was $13.39M.
| Period end | Current Income Tax Expense (Benefit) 12 month | Current Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.62M 10-K · filed 2026-02-25 | |
| 2024-12-31 | $1.97M 10-K · filed 2026-02-25 | |
| 2023-12-31 | $240.00K 10-K · filed 2026-02-25 | -$240.00K 10-K · filed 2024-02-28 |
| 2022-12-31 | $13.39M 10-K · filed 2025-02-26 | -$13.39M 10-K · filed 2024-02-28 |
| 2021-12-31 | -$243.00K 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |